Get the Stockscreener App
24.63
0.53%
0.13
Xencor Inc stock is traded at $24.63, with a volume of 1.15M.
It is up +0.53% in the last 24 hours and down -1.24% over the past month.
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.
See More
Previous Close:
$24.50
Open:
$24.43
24h Volume:
1.15M
Relative Volume:
0.79
Market Cap:
$1.83B
Revenue:
$97.36M
Net Income/Loss:
$-172.42M
P/E Ratio:
-10.72
EPS:
-2.2984
Net Cash Flow:
$-188.84M
1W Performance:
-0.85%
1M Performance:
-1.24%
6M Performance:
+96.57%
1Y Performance:
+88.59%
1-Day Range:
$24.35
$25.38
1-Week Range:
$22.56
$26.03
52-Week Range:
$10.38
$30.61
Xencor Inc Stock (XNCR) Company Profile
Name
Xencor Inc
Sector
Industry
Phone
626-305-5900
Address
465 N. HALSTEAD ST., PASADENA, CA
Compare XNCR vs VRTX, MRNA, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XNCR
Xencor Inc
|
24.63 | 1.83B | 97.36M | -172.42M | -188.84M | -2.2984 |
VRTX
Vertex Pharmaceuticals Inc
|
510.08 | 129.29B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
225.00 | 89.83B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
746.54 | 76.86B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
825.03 | 51.88B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.76 | 40.67B | 742.00K | -1.37B | -1.07B | -7.0731 |
Xencor Inc Stock (XNCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-30-26 | Resumed | Wells Fargo | Overweight |
| Mar-24-26 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-24-25 | Initiated | Truist | Buy |
| Oct-29-25 | Upgrade | Barclays | Underweight → Overweight |
| Sep-17-25 | Resumed | Barclays | Underweight |
| Sep-03-25 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-21-25 | Initiated | William Blair | Outperform |
| Dec-12-24 | Initiated | Wells Fargo | Overweight |
| Dec-02-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-16-24 | Reiterated | BTIG Research | Buy |
| Feb-28-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-19-23 | Initiated | BofA Securities | Buy |
| Dec-06-22 | Initiated | Cowen | Outperform |
| Oct-13-22 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
| Jan-21-22 | Initiated | SMBC Nikko | Outperform |
| Dec-15-21 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Feb-24-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-04-20 | Initiated | Barclays | Underweight |
| Feb-25-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-30-20 | Initiated | RBC Capital Mkts | Outperform |
| Nov-20-19 | Resumed | Guggenheim | Neutral |
| Aug-07-19 | Downgrade | Guggenheim | Buy → Neutral |
| Aug-07-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-13-19 | Initiated | Mizuho | Buy |
| Apr-12-19 | Initiated | Guggenheim | Buy |
| Mar-27-19 | Initiated | Berenberg | Buy |
| Mar-15-19 | Initiated | Raymond James | Outperform |
| Sep-10-18 | Resumed | BTIG Research | Buy |
| Mar-28-18 | Resumed | Leerink Partners | Outperform |
| Mar-02-17 | Initiated | Instinet | Neutral |
| Mar-02-17 | Reiterated | Wedbush | Outperform |
| Oct-04-16 | Initiated | Piper Jaffray | Overweight |
| Dec-22-15 | Initiated | Canaccord Genuity | Buy |
| Aug-05-15 | Reiterated | MLV & Co | Buy |
| Feb-12-15 | Reiterated | Oppenheimer | Outperform |
| Jan-28-15 | Reiterated | MLV & Co | Buy |
| Jul-11-14 | Initiated | Oppenheimer | Outperform |
View All
Xencor Inc Stock (XNCR) Latest News
Xencor stock fell 4.96 percent as targets diverged - AD HOC NEWS
Xencor, Inc. (XNCR) Stock forecasts - Yahoo Finance UK
Trading the Move, Not the Narrative: (XNCR) Edition - Stock Traders Daily
Xencor, Inc. (XNCR) Stock Forecasts - Yahoo Finance
Wells Fargo & Company Initiates Coverage on Xencor (NASDAQ:XNCR) - MarketBeat
Xencor stock falls 3.52 percent as Truist lifts its target - AD HOC NEWS
Xencor (NASDAQ:XNCR) Shares Climb 4.6%Should You Buy? - MarketBeat
Xencor (NASDAQ:XNCR) Earns Buy Rating from Truist Financial - MarketBeat
Truist raises Xencor stock price target to $29 on drug trial outlook - Investing.com Nigeria
Truist Securities reiterates Buy rating on Xencor, $29 price target - TradingView
Truist raises Xencor stock price target to $29 on drug trial outlook - Investing.com
Xencor, Inc. $XNCR Shares Newly Bought by Bank of America Corp DE - MarketBeat
Xencor, Inc. (NASDAQ:XNCR) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Wedbush Maintains Xencor(XNCR.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Xencor, Inc. (XNCR) Stock forecasts - Yahoo Finance Singapore
Xencor, Inc. (XNCR) Stock Forecasts - Yahoo Finance
BofA Adjusts Price Target on Xencor to $26 From $20, Keeps Neutral Rating - Yahoo Finance
Xencor (XNCR) Holds Near $23.84 as Shares Consolidate Between Key LevelsATR Stop - careplusvn.com
Hsbc Holdings PLC Has $2.08 Million Position in Xencor, Inc. $XNCR - MarketBeat
Barclays Maintains Xencor(XNCR.US) With Buy Rating, Raises Target Price to $35 - moomoo.com
Xencor at 12th Annual Cantor Fitzgerald Global Healthcare Conference: late-stage shift - investing.com
Xencor at 12th Annual Cantor Fitzgerald Global Healthcare Conference: late-stage shift - Investing.com Canada
Xencor at 12th Annual Cantor Fitzgerald Global Healthcare Conference: late-stage shift - Investing.com UK
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 260,752 Shares of Xencor, Inc. $XNCR - MarketBeat
The Manufacturers Life Insurance Company Buys Shares of 49,696 Xencor, Inc. $XNCR - MarketBeat
XNCR stock holds steady as Xencor eyes next trial milestones - ad-hoc-news.de
Seven Fleet Capital Management LP Has $5.93 Million Stake in Xencor, Inc. $XNCR - MarketBeat
Man Group plc Takes Position in Xencor, Inc. $XNCR - MarketBeat
Bank of New York Mellon Corp Makes New Investment in Xencor, Inc. $XNCR - MarketBeat
XNCR Maintained by JP Morgan -- Price Target Raised to $21.00 - GuruFocus
JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Xencor (NASDAQ:XNCR) Stock - MarketBeat
Technical Reactions to XNCR Trends in Macro Strategies - Stock Traders Daily
Xencor to Present at the 2026 Cantor Global Healthcare Conference - BioSpace
Xencor to Present at the 2026 Cantor Global Healthcare Conference - marketscreener.com
Xencor to Present at the 2026 Cantor Global Healthcare Conference - Business Wire
Xencor to Present at the 2026 Cantor Global Healthcare Conference - Yahoo Finance
Xencor (XNCR) Maintained by Raymond James -- Price Target Raised to $46 - GuruFocus
Raymond James Adjusts Xencor Price Target to $46 From $40, Maintains Strong Buy Rating - marketscreener.com
Xencor, Inc. (NASDAQ:XNCR) Given Consensus Recommendation of "Hold" by Brokerages - marketbeat.com
Xencor (NASDAQ:XNCR) Sees Large Volume IncreaseHere's What Happened - MarketBeat
Hsbc Holdings PLC Buys Shares of 125,482 Xencor, Inc. $XNCR - MarketBeat
Legal & General Group Plc Acquires Shares of 1,091,177 Xencor, Inc. $XNCR - MarketBeat
Deutsche Bank AG Acquires New Shares in Xencor, Inc. $XNCR - marketbeat.com
Bank of America Corp DE Sells 263,315 Shares of Xencor, Inc. $XNCR - marketbeat.com
BlackRock Inc. Buys Shares of 13,651,261 Xencor, Inc. $XNCR - MarketBeat
Xencor (NASDAQ:XNCR) Stock Price Down 9%What's Next? - MarketBeat
368,305 Shares in Xencor, Inc. $XNCR Bought by Seven Fleet Capital Management LP - MarketBeat
ADAR1 Capital Management LLC Invests $3.74 Million in Xencor, Inc. $XNCR - MarketBeat
Primecap Management Co. CA Invests $163.92 Million in Xencor, Inc. $XNCR - MarketBeat
Xencor (NASDAQ:XNCR) Reaches New 52-Week HighHere's Why - MarketBeat
Xencor Inc Stock (XNCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Xencor Inc Stock (XNCR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Feigal Ellen | Director |
Jun 18 '26 |
Proposed Sale |
13.06 |
6,843 |
89,370 |
0 |
| GORMAN KEVIN CHARLES | Director |
Jun 15 '26 |
Proposed Sale |
12.31 |
7,527 |
92,657 |
0 |
| GUSTAFSON KURT A | Director |
Jun 15 '26 |
Proposed Sale |
12.31 |
5,474 |
67,385 |
0 |
| RANIERI RICHARD J | Director |
Jun 15 '26 |
Proposed Sale |
12.31 |
5,474 |
67,385 |
0 |
| Montgomery Alan Bruce | Director |
Jun 15 '26 |
Proposed Sale |
12.31 |
5,064 |
62,338 |
0 |
| Montgomery Alan Bruce | Director |
Jun 15 '26 |
Sale |
12.31 |
5,064 |
62,338 |
15,547 |
| RANIERI RICHARD J | Director |
Jun 15 '26 |
Sale |
12.31 |
5,474 |
67,385 |
13,709 |
| GORMAN KEVIN CHARLES | Director |
Jun 15 '26 |
Sale |
12.31 |
7,527 |
92,657 |
11,378 |
| GUSTAFSON KURT A | Director |
Jun 15 '26 |
Sale |
12.31 |
5,474 |
67,385 |
14,709 |
| Cornelissen Bart Jan | SR. VICE PRESIDENT & CFO |
Apr 10 '26 |
Sale |
12.29 |
3,499 |
42,990 |
75,898 |
1.26%
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):